CUE BIOPHARMA INC (CUE) Fundamental Analysis & Valuation

NASDAQ:CUE • US22978P1066

Current stock price

28.5001 USD
+13.76 (+93.35%)
Last:

This CUE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CUE Profitability Analysis

1.1 Basic Checks

  • In the past year CUE has reported negative net income.
  • CUE had a negative operating cash flow in the past year.
  • CUE had negative earnings in each of the past 5 years.
  • CUE had a negative operating cash flow in each of the past 5 years.
CUE Yearly Net Income VS EBIT VS OCF VS FCFCUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M -50M

1.2 Ratios

  • CUE has a Return On Assets of -63.02%. This is in the lower half of the industry: CUE underperforms 61.75% of its industry peers.
  • CUE has a Return On Equity of -100.64%. This is comparable to the rest of the industry: CUE outperforms 42.52% of its industry peers.
Industry RankSector Rank
ROA -63.02%
ROE -100.64%
ROIC N/A
ROA(3y)-90.61%
ROA(5y)-76.57%
ROE(3y)-156.63%
ROE(5y)-123.6%
ROIC(3y)N/A
ROIC(5y)N/A
CUE Yearly ROA, ROE, ROICCUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

1.3 Margins

  • CUE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CUE Yearly Profit, Operating, Gross MarginsCUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. CUE Health Analysis

2.1 Basic Checks

  • CUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CUE has more shares outstanding
  • CUE has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for CUE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CUE Yearly Shares OutstandingCUE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
CUE Yearly Total Debt VS Total AssetsCUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • An Altman-Z score of 41.76 indicates that CUE is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of CUE (41.76) is better than 94.37% of its industry peers.
  • CUE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 41.76
ROIC/WACCN/A
WACC9.51%
CUE Yearly LT Debt VS Equity VS FCFCUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M 60M

2.3 Liquidity

  • CUE has a Current Ratio of 2.74. This indicates that CUE is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.74, CUE is not doing good in the industry: 66.80% of the companies in the same industry are doing better.
  • A Quick Ratio of 2.74 indicates that CUE has no problem at all paying its short term obligations.
  • CUE's Quick ratio of 2.74 is on the low side compared to the rest of the industry. CUE is outperformed by 64.47% of its industry peers.
Industry RankSector Rank
Current Ratio 2.74
Quick Ratio 2.74
CUE Yearly Current Assets VS Current LiabilitesCUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CUE Growth Analysis

3.1 Past

  • CUE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.19%, which is quite impressive.
  • The Revenue has grown by 195.75% in the past year. This is a very strong growth!
  • Measured over the past years, CUE shows a very strong growth in Revenue. The Revenue has been growing by 54.20% on average per year.
EPS 1Y (TTM)58.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%111.52%
Revenue 1Y (TTM)195.75%
Revenue growth 3Y180.09%
Revenue growth 5Y54.2%
Sales Q2Q%1292.26%

3.2 Future

  • Based on estimates for the next years, CUE will show a decrease in Earnings Per Share. The EPS will decrease by -2.33% on average per year.
  • Based on estimates for the next years, CUE will show a very negative growth in Revenue. The Revenue will decrease by -34.02% on average per year.
EPS Next Y-41.46%
EPS Next 2Y-20.97%
EPS Next 3Y37.25%
EPS Next 5Y-2.33%
Revenue Next Year-87.5%
Revenue Next 2Y-64.64%
Revenue Next 3Y89.51%
Revenue Next 5Y-34.02%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CUE Yearly Revenue VS EstimatesCUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 20M 40M 60M 80M
CUE Yearly EPS VS EstimatesCUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

1

4. CUE Valuation Analysis

4.1 Price/Earnings Ratio

  • CUE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CUE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CUE Price Earnings VS Forward Price EarningsCUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CUE Per share dataCUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

  • CUE's earnings are expected to grow with 37.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.97%
EPS Next 3Y37.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CUE Dividend Analysis

5.1 Amount

  • CUE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CUE Fundamentals: All Metrics, Ratios and Statistics

CUE BIOPHARMA INC

NASDAQ:CUE (5/1/2026, 9:41:09 AM)

28.5001

+13.76 (+93.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)03-24
Earnings (Next)05-12
Inst Owners22.31%
Inst Owner Change0%
Ins Owners0.4%
Ins Owner Change12.61%
Market Cap2.78B
Revenue(TTM)27.47M
Net Income(TTM)-26.60M
Analysts80
Price TargetN/A
Short Float %N/A
Short Ratio0.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)380.95%
Min Revenue beat(2)-7.09%
Max Revenue beat(2)768.99%
Revenue beat(4)2
Avg Revenue beat(4)179.23%
Min Revenue beat(4)-67.11%
Max Revenue beat(4)768.99%
Revenue beat(8)5
Avg Revenue beat(8)121.29%
Revenue beat(12)8
Avg Revenue beat(12)85.76%
Revenue beat(16)9
Avg Revenue beat(16)51.44%
PT rev (1m)0%
PT rev (3m)-20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-20.83%
EPS NY rev (3m)-20.83%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-90%
Revenue NY rev (3m)-90%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 101.34
P/FCF N/A
P/OCF N/A
P/B 105.3
P/tB 105.3
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0.28
BVpS0.27
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -63.02%
ROE -100.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.61%
ROA(5y)-76.57%
ROE(3y)-156.63%
ROE(5y)-123.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.48%
Cap/Sales 0.64%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.74
Quick Ratio 2.74
Altman-Z 41.76
F-Score6
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)11.7%
Cap/Depr(5y)25.16%
Cap/Sales(3y)0.45%
Cap/Sales(5y)4.21%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%111.52%
EPS Next Y-41.46%
EPS Next 2Y-20.97%
EPS Next 3Y37.25%
EPS Next 5Y-2.33%
Revenue 1Y (TTM)195.75%
Revenue growth 3Y180.09%
Revenue growth 5Y54.2%
Sales Q2Q%1292.26%
Revenue Next Year-87.5%
Revenue Next 2Y-64.64%
Revenue Next 3Y89.51%
Revenue Next 5Y-34.02%
EBIT growth 1Y36.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.3%
OCF growth 3YN/A
OCF growth 5YN/A

CUE BIOPHARMA INC / CUE Fundamental Analysis FAQ

What is the fundamental rating for CUE stock?

ChartMill assigns a fundamental rating of 3 / 10 to CUE.


Can you provide the valuation status for CUE BIOPHARMA INC?

ChartMill assigns a valuation rating of 1 / 10 to CUE BIOPHARMA INC (CUE). This can be considered as Overvalued.


How profitable is CUE BIOPHARMA INC (CUE) stock?

CUE BIOPHARMA INC (CUE) has a profitability rating of 0 / 10.